“We have run out of chemotherapy options for this patient, so we have referred them for surgical evaluation to see if cytoreductive surgery and HIPEC is an option.” Clearly not all patients with PM ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses new data from the TRUST trial, which were ...

Declining cytoreductive surgery in advanced EOC is associated with significantly poorer survival outcomes compared to those who undergo the procedure. Sociodemographic factors, including race, age, ...

Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130 The study ...

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced positive interim clinical results from an ongoing Phase 2 study of its lead clinical development candidate, pegsitacianine, ...

Neoadjuvant chemotherapy followed by interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) significantly improves progression-free survival (PFS) and overall survival ...

Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery significantly improved overall survival (OS) in women with platinum-sensitive, recurrent epithelial ovarian carcinoma, ...

NACT followed by ICS significantly improves 3-year PFS and OS in advanced ovarian cancer compared to chemotherapy alone. Patients undergoing NACT and ICS had better outcomes than those receiving only ...

The optimal timing of surgery in patients with resectable advanced ovarian cancer remains controversial. Should these patients receive the standard radical surgery followed by chemotherapy, or could ...

There is not enough evidence about how well this procedure works or how safe it is. This type of procedure can cause complications. So it can only be done with special arrangements. This means you ...